Diligence memo · auto-generated · as of July 2, 2026

Opprtna Therapeutics, Inc.

Opprtna Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Opprtna Therapeutics, Inc. operates in Biotechnology, based in MANSFIELD.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Opprtna Therapeutics, Inc. has raised $125K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $125K on 2024-05-08.

Most recent recorded round closed around 2024-05-08.

Valuation (modeled)modeled

Provath models Opprtna Therapeutics, Inc. at approximately $633K (range $67K–$2.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.20× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 2% of Biotechnology peers (4293 compared).

Modeled value ranks above 1% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.